B BioPulse
Clinical Trials Sep 08, 2026 · 1 min read · 16,473 views

Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins

I

Isabella Hart

Editorial · Sep 08, 2026

Moderna's $2B offering; AstraZeneca-Amgen and Biokin chalk up Phase 3 wins

Plus news about Takeda China and ProFound. Moderna's $2B offering: The mRNA biotech will offer convertible senior notes for the "flexibility to invest" in growing its oncology

Read Original Source Back to Feed

← Previous

Nvidia-backed Iambic files for IPO, disclosing new clinic and dealmaking details

Next →

Makary pushes for IRB reforms to catch China's speedy trial starts

Related Reading

Roche kidney drug's Phase 3 win sets up path to accelerated approval
Clinical Trials

Roche kidney drug's Phase 3 win sets up path to accelerated approval

Sep 28, 2026

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
Clinical Trials

RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win

Sep 27, 2026

Akeso details survival win for its PD-1xVEGF drug versus Keytruda
Clinical Trials

Akeso details survival win for its PD-1xVEGF drug versus Keytruda

Sep 27, 2026